Cyteir Announces Liquidating Distribution
LEXINGTON, MA— April 12, 2024 — Cyteir Therapeutics, Inc. (“Cyteir” or the “Company”) today announced that Cyteir has initiated a cash liquidating distribution of $115,939,606.84 to stockholders of record of the Company’s common stock as of March 20, 2024 (the “Final Record Date”). As a result, each stockholder of record of the Company’s common stock as of the Final Record Date is entitled to receive a pro rata portion of the liquidating distribution, which is equal to $3.16 per share (the “Liquidating Distribution”).
The Liquidating Distribution is part of Cyteir’s Plan of Complete Liquidation and Dissolution (the “Plan”) previously approved by Cyteir’s board of directors and by Cyteir’s stockholders at a special meeting held on November 16, 2023. Pursuant to the Plan, on March 20, 2024, Cyteir filed a certificate of dissolution with the Secretary of State of the State of Delaware. The certificate of dissolution, which became effective upon filing, provided for the dissolution of the Company under the General Corporation Law of the State of Delaware.
Cyteir intends to make one or more additional liquidating distributions to the extent sufficient cash is available for distribution; however, Cyteir cannot predict with certainty the amount or timing of any additional liquidating distributions. No assurances can be made that sufficient assets will be available for any additional distribution.
Inquiries should be directed to: [email protected]